Immuron (IMRN) Liabilities and Shareholders Equity (2016 - 2025)
Immuron (IMRN) posted quarterly Liabilities and Shareholders Equity of $100926.2 for Q3 2025, down 35.1% year-over-year from $155499.7 in Q3 2024, and down 98.44% quarter-over-quarter from $6.5 million in Q2 2025.
Immuron (IMRN) Liabilities and Shareholders Equity (2016 - 2025) Analysis & Trends
Immuron's Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $100926.2 for Q3 2025.
- In Q3 2025, Liabilities and Shareholders Equity fell 35.1% year-over-year to $100926.2; the TTM figure through Sep 2025 stood at $14.7 million (down 41.06% YoY), while the FY2025 annual figure was $100926.2, down 35.1% from the prior year.
- Liabilities and Shareholders Equity for Q3 2025 stood at $100926.2, down from $6.5 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $20.8 million in Q2 2021, with the low at $100926.2 in Q3 2025.
- The 5-year median for Liabilities and Shareholders Equity is $8.0 million (2024), against an average of $8.6 million.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity soared 8691.06% in 2022, then plunged 99.21% in 2023.
- Immuron's Liabilities and Shareholders Equity stood at $185766.3 in 2021, then jumped by 8691.06% to $16.3 million in 2022, then sank by 99.21% to $129434.6 in 2023, then jumped by 6048.66% to $8.0 million in 2024, then slumped by 98.73% to $100926.2 in 2025.
- Business Quant data shows IMRN's Liabilities and Shareholders Equity at $100926.2 in Q3 2025, $6.5 million in Q2 2025, and $8.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Immuron | 6.75 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 100,926.19 |
| Jun 30, 2025 | 6.49 Mn |
| Dec 31, 2024 | 7.96 Mn |
| Sep 9, 2024 | 155,499.69 |
| Jun 30, 2024 | 10.25 Mn |
| Dec 31, 2023 | 129,434.59 |
| Sep 28, 2023 | 14.41 Mn |
| Jun 30, 2023 | 219,881.82 |
| Dec 31, 2022 | 16.33 Mn |
| Aug 31, 2022 | 17.29 Mn |
| Jun 30, 2022 | 17.80 Mn |
| Dec 31, 2021 | 185,766.29 |
| Jun 30, 2021 | 20.83 Mn |
| Dec 31, 2020 | 290,636.97 |
| Jun 30, 2020 | 4.07 Mn |
| Dec 31, 2019 | 62,021.63 |
| Jun 30, 2019 | 6.00 Mn |
| Dec 31, 2018 | 7.70 Mn |
| Jun 30, 2018 | 7.00 Mn |
| Dec 31, 2017 | 4.80 Mn |